This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The $504,732 award to Aphios Corp, a minority-owned biotechnology company, will support two phases of research. In Phase I, the company will nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, characterize the formulations, and evaluate their impact on in vitro models of brain...
The National Institute on Aging (NIA) awarded a $949,062 Project Grant (CFDA 93.866) to Somatoceutics LLC to develop a non-toxic, peptide-based nanomaterial (SMC-101 nanotubes) for delivering drugs across the blood-brain barrier to treat Alzheimer's disease and other dementias. The objectives are to optimize the nanotubes for drug-loading and transcytosis across a blood-brain barrier model in vitro, and then evaluate their toxicity and ability to deliver the drug galantamine to the central...
This federal Project Grant award of $513,740.00 was provided by the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), to develop a novel exosome-based nano-scavenger (EBNS) for the targeted removal of amyloid-beta (Aβ) proteins associated with Alzheimer's disease (AD) and other amyloid-related disorders. The 3-year project aims to: 1) genetically engineer exosomes to load Aβ-targeting antibodies and Aβ-degrading enzymes; 2) establish isolation and...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $479,375 to Florida International University to conduct research on the effect of a small molecule activator of autophagy, TPI-132, on insulin signaling, senescence, and neuropathology in mouse models of Alzheimer's disease. The goal is to optimize TPI-132 to increase its potency, brain penetration, and reduce toxicity, and then evaluate its impacts on neuronal senescence, synapses, protein...
The National Institute on Aging (NIA) awarded a $1,783,700.00 Project Grant under the Aging Research program (CFDA 93.866) to the University of Illinois to develop novel blood-brain barrier permeable multimodal imaging agents for the diagnosis of neurodegenerative diseases, with a focus on Alzheimer's disease and related dementias. The 3-year grant aims to employ organic and inorganic chemical design principles to generate diagnostic agents capable of detecting protein aggregation,...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), aims to develop novel lipid nanoparticle (LNP) formulations for delivering nucleic acid-based therapeutics to the brain for treating Alzheimer's disease (AD). The $835,417 award will support research to synthesize BBB-crossing lipids, formulate LNP-RNA constructs, elucidate their trafficking across the blood-brain barrier, engineer siRNA and mRNA sequences to modulate APOE...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $445,625 to Rutgers, The State University to develop an innovative nanotechnology approach to interrupt amyloid-beta (Aβ) aggregation and attenuate neuroinflammation in Alzheimer's disease (AD). The key objectives are to: (1) elucidate how scavenger receptor-targeted nanoparticles can ameliorate Aβ-mediated pathological glial communications, and (2) evaluate the longer-term neuroprotective...
The National Institute on Aging (NIA) awarded a $1,512,892 Project Grant under the Aging Research program (CFDA 93.866) to 3P Biotechnologies, Inc. to develop a targeted nanoformulation delivery system for the bioactive curcuminoids, curcumin and bisdemethoxycurcumin, to treat Alzheimer's disease (AD). The Phase I project aims to optimize exosome-based formulations of these compounds and assess their biodistribution and toxicity in mice, as well as determine the efficacy of folic...
This Project Grant award for $506,451 from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) aims to develop an effective targeted delivery system for small interfering RNA (siRNA) therapeutics to mitigate neuroinflammatory diseases, including Alzheimer's disease. The project leverages the awardee's 3P Biotechnologies, Inc.'s expertise in exosome engineering, drug delivery, and siRNA therapeutics. The key products or services to be delivered under this award...
The National Institute on Aging (NIA) awarded a $295,000 Project Grant (CFDA 93.866 - Aging Research) to Florida International University to develop biotherapeutic nanogels for the treatment of Alzheimer's disease. The goal is to create a novel nanogel system that can effectively cross the blood-brain barrier, inhibit amyloid-beta aggregation, and reduce oxidative stress and neuroinflammation associated with Alzheimer's. The project will focus on improving the nanogel formulation for enhanced brain penetration and evaluating its in vivo efficacy in a mouse model of Alzheimer's disease, examining its impact on amyloid and tau pathology, neuroinflammation, dendritic spines, and cognitive function. This research aims to address an important unmet clinical need in Alzheimer's disease treatment by developing a multifunctional nanogel-based therapy.